Q-omics provides the consensus-scored H4C12 profile across patient tissues and cancer cell-line models. H4C12 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in SCLC. Among the 18 cancer types available for tumor–normal comparison, H4C12 is differentially expressed in 10, with the highest sampling consensus in HNSC. Additionally, H4C12 RNA expression shows 15,923 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight SCLC, HNSC, and LSCC as cancer lineages where H4C12 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for H4C12 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes H4C12 survival associations across molecular data types. H4C12 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible H4C12 RNA expression–survival associations across cancer types. High H4C12 expression shows unfavorable associations in UCEC, KIRC, KICH and ACC, but favorable associations in SCLC and MESO. The SCLC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SCLC as the clearest survival context for H4C12 RNA expression.
This table summarizes H4C12 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for H4C12. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. H4C12 shows higher tumor expression in HNSC, LIHC, LUAD, BLCA, BRCA and LUSC. The HNSC box plot shows higher H4C12 RNA expression in tumor versus normal tissue (log2 FC = +0.920, t-test p < 0.001).
This table shows molecular features associated with H4C12 in patient tissues and cancer cell lines. In patient samples, H4C12 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, H4C12 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LIVER.
